Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Atara Biotherapeutics (ATRA) Net Margin (2022 - 2025)

Atara Biotherapeutics' Net Margin history spans 4 years, with the latest figure at 213.54% for Q4 2025.

  • For Q4 2025, Net Margin fell 17511.0% year-over-year to 213.54%; the TTM value through Dec 2025 reached 27.07%, up 9322.0%, while the annual FY2025 figure was 27.07%, 9322.0% up from the prior year.
  • Net Margin reached 213.54% in Q4 2025 per ATRA's latest filing, down from 124.62% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 38.73% in Q1 2025 to a low of 33742.99% in Q4 2022.
  • Average Net Margin over 4 years is 3718.62%, with a median of 169.08% recorded in 2025.
  • The largest YoY upside for Net Margin was 3229398bps in 2023 against a maximum downside of -900276bps in 2023.
  • A 4-year view of Net Margin shows it stood at 33742.99% in 2022, then surged by 96bps to 1449.01% in 2023, then skyrocketed by 97bps to 38.44% in 2024, then plummeted by -456bps to 213.54% in 2025.
  • Per Business Quant, the three most recent readings for ATRA's Net Margin are 213.54% (Q4 2025), 124.62% (Q3 2025), and 13.58% (Q2 2025).